Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

Open access
Zolla-Pazner, Susan, deCamp, Allan, Gilbert, Peter B., Williams, Constance, Yates, Nicole L., Williams, William T., Howington, Robert, Fong, Youyi, Morris, Daryl E., Soderberg, Kelly A., Irene, Carmela, Reichman, Charles, Pinter, Abraham, Parks, Robert, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Andrews, Charla, O’Connell, Robert J., Yang, Zhi-yong, Nabel, Gary J., Kim, Jerome H., Michael, Nelson L., Montefiori, David C., Liao, Hua-Xin, Haynes, Barton F., Tomaras, Georgia D. · 2014 · PLoS ONE

Abstract

UNLABELLED: In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate of risk of HIV-1 infection. To determine if V1V2-specific Abs cross-react with V1V2 from different HIV-1 subtypes, if the nature of the V1V2 antigen used to asses cross-reactivity influenced infection risk, and to identify immune assays for upcoming HIV-1 vaccine efficacy trials, new V1V2-scaffold antigens were designed and tested. Protein scaffold antigens carrying the V1V2 regions from HIV-1 subtypes A, B, C, D or CRF01_AE were assayed in pilot studies, and six were selected to assess cross-reactive Abs in the plasma from the original RV144 case-control cohort (41 infected vaccinees, 205 frequency-matched uninfected vaccinees, and 40 placebo recipients) using ELISA and a binding Ab multiplex assay. IgG levels to these antigens were assessed as correlates of risk in vaccine recipients using weighted logistic regression models. Levels of Abs reactive with subtype A, B, C and CRF01_AE V1V2-scaffold antigens were all significant inverse correlates of risk (p-values of 0.0008-0.05; estimated odds ratios of 0.53-0.68 per 1 standard deviation increase). Thus, levels of vaccine-induced IgG Abs recognizing V1V2 regions from multiple HIV-1 subtypes, and presented on different scaffolds, constitute inverse correlates of risk for HIV-1 infection in the RV144 vaccine trial. The V1V2 antigens provide a link between RV144 and upcoming HIV-1 vaccine trials, and identify reagents and methods for evaluating V1V2 Abs as possible correlates of protection against HIV-1 infection. TRIAL REGISTRATION: ClinicalTrials.gov NCT00223080.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0087572

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 267

Metadata

Authors
Zolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., Irene, C., Reichman, C., Pinter, A., Parks, R., Pitisuttithum, P., Kaewkungwal, J., Rerks-Ngarm, S., Nitayaphan, S., Andrews, C., O’Connell, R. J., Yang, Z.-Y., Nabel, G. J., Kim, J. H., Michael, N. L., Montefiori, D. C., Liao, H.-X., Haynes, B. F., & Tomaras, G. D.
Venue
PLoS ONE
Published
2014-02-04
Volume
9
Issue
2
Pages
e87572
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2036297695
Cited by
267
References
26
FWCI
17.54
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. https://app.cochat.ai/papers/10.1371/journal.pone.0087572
The paper
Zolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., Irene, C., Reichman, C., Pinter, A., Parks, R., Pitisuttithum, P., Kaewkungwal, J., Rerks-Ngarm, S., Nitayaphan, S., Andrews, C., . . . Tomaras, G. D. (2014). Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. PLoS ONE. https://doi.org/10.1371/journal.pone.0087572

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.